Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease. The stock was down 33.6% to $2.63 in late trading, well under its 52-week low of $3.49.
For the past few years, researchers have been testing the medicine, known as AL002, in a clinical trial that enrolled close ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.
The drug, called AL002, is designed to activate a group of surveilling neuronal immune cells called microglia. It was among ...
Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...
Alector is preparing to release phase 2 INVOKE-2 data for AL002, a candidate targeting TREM2, which has shown potential in earlier trials. The interest in TREM2 therapies has been bolstered by ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback